Quanterix's Simoa Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light To Assess Neurological Disease Activity In Pediatric Patients
Portfolio Pulse from Benzinga Newsdesk
Quanterix's Simoa technology has been used in a large international reference range study to assess neurological disease activity in pediatric patients using serum neurofilament light. The study could potentially lead to significant advancements in the field of pediatric neurology.
July 31, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quanterix's Simoa technology is being used in a significant study, which could potentially lead to advancements in pediatric neurology. This could enhance the company's reputation and demand for its technology.
The use of Quanterix's Simoa technology in a large international study signifies its importance and reliability in the field of medical research. If the study leads to significant advancements in pediatric neurology, it could increase the demand for Simoa technology, positively impacting Quanterix's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100